Abstract:Liver cancer has posed a huge disease burden on the Korean population. Liver cancer is the 4th most common cancer in Korea after stomach cancer, colon cancer and lung cancer in order. Chronic viral hepatitis B and C are the major causes of hepatocellular carcinoma (HCC) in Korea. Especially, hepatitis B virus infection rate is very high and over 70% of HCC is related to hepatitis B infection. In the pre-vaccination era before 1980s, 6.6∼8.6% of the general Korean population tested positive for HBsAg. To reduce the high disease burden of hepatitis B, the Korean Government implemented public health programs such as universal viral hepatitis B vaccination for neonates in 1995 and vertical transmission prevention program for the neonates from HBsAg positive mothers in 2002. The HBsAg positive rate has been decreasing thanks to the success of those vaccination programs. The HBsAg positive rate in adults aged over 20 years is about 4% and less than 1% in aged less than 20 years in 2012 according to the Korea National Health and Nutrition Survey data. Through vertical transmission prevention program initiated in 2002, hepatitis B immunoglobulin and hepatitis B vaccination were provided to about 170,000 neonates and the success rate of the vertical transmission reached about 97%. Also the cost for the diagnosis and treatment of acute and chronic hepatitis B is covered by the National Health Insurance. Hepatitis C infection rate is less than 1% in individuals aged less than 50 years – 0% in aged 10∼18, 0.1% in aged 19∼29, 0.3% in aged 20∼39, 0.9% in aged 40∼49 – and 1∼2% in aged older than 50 years. The cost for the diagnosis and treatment of chronic hepatitis C is covered by the National Health Insurance like hepatitis B as well. Despite of the successful implementation of the National Immunization Program, the disease burden of viral hepatitis and liver cancer is still high in Korea, various programs to reduce the disease burden should be in place in the future.

Contents Vol. 7, 2018

Contents Vol. 8, 2019

The 5th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2014): A Bridge to a Consensus on HCC Management, Taipei, Taiwan, July 11-13, 2014

[Ten-Year Retrospect of ALPPS in the Treatment of Hepatocellular Carcinoma:An Eternal Concept with Cautious Technologic Choice].

Vol. 116, February 2018

HBPD: Table of Contents Vol. 7, No. 4, 2008

Plenary Paper

Contents Vol. 5, 2019

The 4th Asia-Pacific Primary Liver Cancer Expert Meeting

APASL Clinical Practice Guidelines on Systemic Therapy for Hepatocellular Carcinoma-2024

Advances in hepatopancreatobiliary surgery of the 13th World Congress of the International Hepato-Pancreato-Biliary Association

Asia–Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update

Pan-Asian Adapted ESMO Clinical Practice Guidelines for the Management of Patients with Intermediate and Advanced/relapsed Hepatocellular Carcinoma: a TOS-ESMO Initiative Endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO

Advances in the 8th Japan-China Hepato-Pancreato-Biliary Symposium

Lapatinib in Combination with Capecitabine Plus Oxaliplatin (capeox) in Her2 Positive Advanced or Metastatic Gastric (a/mgc), Esophageal (eac), or Gastroesophageal (gej) Adenocarcinoma: the Logic Trial.

Editorial: Interventional Therapy of Hepatocellular Carcinoma

A Changing Paradigm for the Treatment of Intermediate-Stage Hepatocellular Carcinoma: Asia-Pacific Primary Liver Cancer Expert Consensus Statements

Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2019 Edition).

Multidisciplinary Management of Nonresectable Hepatocellular Carcinoma

Novel Imaging Diagnosis for Hepatocellular Carcinoma: Consensus from the 5th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2014).

World Gastroenterology Organisation Guideline. Hepatocellular Carcinoma (HCC): a Global Perspective.